|1.||Penney, C: 1 article (09/2000)|
|2.||Connolly, T: 1 article (09/2000)|
|3.||Gagnon, L: 1 article (09/2000)|
|4.||Heibein, J: 1 article (09/2000)|
|5.||Zacharie, B: 1 article (09/2000)|
|6.||Kadhim, S: 1 article (09/2000)|
|7.||Attardo, G: 1 article (09/2000)|
|8.||Lagraoui, M: 1 article (09/2000)|
09/01/2000 - "In the MC38 tumor model, combination treatment of established tumors with BCH-1393 and Cy (CTX) at 50 mg/kg resulted in a significant delay in tumor growth compared to CTX treatment alone. "
09/01/2000 - "Combination treatment of 50 mg/kg BCH-1393 with 100 mg/kg Cy (given as single intravenous bolus injection) starting 2 days prior to DA-3 tumor cell inoculation prevented tumor outgrowth in 70-80% of treated mice. "
09/01/2000 - "However, a significant inhibition of tumor outgrowth and suppression of established tumor growth was observed when BCH-1393 was administered in combination with subtherapeutic doses of Cy. "
09/01/2000 - "Prompted by this evidence, we extended evaluation of BCH-1393 for anticancer activity in syngeneic mouse experimental tumor models. "
09/01/2000 - "Daily intraperitoneal injection of BCH-1393 at 50 mg/kg alone was well tolerated but produced a relatively weak anti-tumor effect in both tumor models. "